Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

Original reporting
Published Oct 29, 2026, 6:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians — source image
Decision brief

The 30-second read

$REPLBullishHigh
01

Why it matters

The 17% share surge reflects market enthusiasm for the new therapy, but future performance hinges on sales data and continued cash runway.

02

Market read

The article provides fresh, material information on a biotech launch that moved the stock sharply, offering a clear trading opportunity.

03

What to watch

Potential competition from Amgen's Imlygic and the need for continued cash to fund the launch.

Relevance 7/10Novelty 7/10Timing: today, intraday

Background

Replimune's TUDRIQEV is an oncolytic virus therapy for melanoma, administered with Bristol Myers' Opdivo.

Company-level read

Ticker impact

$REPLBullishMedium confidence
Context

Replimune shares jumped 17% after the first three weeks of its TUDRIQEV melanoma launch saw prescriptions at over 15 institutions.

Expected impact

likely upward pressure as investors price in accelerating sales and potential revenue growth.

Evidence & confidence

First‑hand uptake data and a double‑digit intraday move indicate fresh catalyst; however, sales figures are still pending.

Market effects

Oncolytic virus therapies may see heightened investor interest, benefiting the biotech sector.

U.S. biotech market receives a boost from the launch news.

Limited to companies developing similar tumor‑injection therapies.

Counterpoint

The launch may face higher-than-expected costs and regulatory hurdles, tempering upside.

Key entities

  • Replimune Group

    Developer of TUDRIQEV, subject of the article.

Related articles

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.

$REPLMed

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.